Sjögren's disease: trials for referral
92 open trials in the registries we read. Each row links to its registry record.
Registry data only. Frontlight does not judge whether a patient can take part: the trial team decides.
Where the open trials are
Type a city to sort by distance. The distance is worked out in your browser; the city is not sent anywhere.
92 trials shown
Phase 12 sites
Not yet recruitingUnited States
NCT06297213
R-2487 in Patients With Sjogren's Syndrome (SjD)
Rise Therapeutics LLC
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingAustralia
NCT07649265
A Trial in Healthy Adult Participants and Adults With Autoimmune Diseases to Test How HBM7020 is Tolerated and How it Behaves in the Body
Otsuka Pharmaceutical Development & Commercialization, Inc.
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govNo phase1 site
Not yet recruitingChina
NCT07901764
MYTP01 for Immune-Mediated Diseases
Zhejiang Provincial People's Hospital
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingUnited States
NCT07281456
Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease
National Institute of Dental and Craniofacial Research (NIDCR)
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 10 sites
Not yet recruiting
NCT07906145
A Phase 1 Study of QLS2416 Injection in Participants With Autoimmune Diseases
Shanghai Qilu Pharmaceutical Research and Development Center LTD
Registry updated 30 Oct 2026
Registry record: ClinicalTrials.govPhase 27 sites
RecruitingAustralia
NCT07118241
A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CONTROLLED STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 µG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASE
Lubris Bio Pty Ltd
Registry updated 28 Oct 2026
Registry record: ClinicalTrials.govPhase 274 sites
RecruitingAustria, Australia, Belgium, Bulgaria, Canada, China
NCT07737743
A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease
Novartis Pharmaceuticals
Registry updated 28 Oct 2026
Registry record: ClinicalTrials.govPhase 122 sites
RecruitingChina
NCT07732309
A Study of ATG-201 in Adult Participants With Autoimmune Diseases
Antengene Biologics Limited
Registry updated 28 Oct 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingAustralia
NCT07712939
A Phase 1, First-in-Human Study of CND319 in Healthy Participants and Patients With Rheumatic Diseases
Candid Therapeutics
Registry updated 21 Oct 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingChina
NCT07413341
A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases
Therorna
Registry updated 19 Oct 2026
Registry record: ClinicalTrials.govPhase 3111 sites
RecruitingBelgium, Bulgaria, Germany, Spain, France, Georgia
NCT07404865
Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease
Vor Biopharma
Registry updated 19 Oct 2026
Registry record: ClinicalTrials.govPhase 123 sites
Not yet recruitingBelgium, Germany, France, Netherlands, Poland, United States
NCT07873931
A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
Bristol-Myers Squibb
Registry updated 14 Oct 2026
Registry record: ClinicalTrials.govPhase 3104 sites
RecruitingAustria, Australia, Canada, China, Czechia, Germany
NCT07621809
Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
Novartis Pharmaceuticals
Registry updated 13 Oct 2026
Registry record: ClinicalTrials.govPhase 152 sites
RecruitingCanada, United States
NCT03816345
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
National Cancer Institute (NCI)
Registry updated 5 Oct 2026
Registry record: ClinicalTrials.govNo phase1 site
RecruitingFrance
NCT06875102
Fatigue in Sjögren's Syndrome: 3 Therapeutic Strategies
Centre Hospitalier Universitaire de Saint Etienne
Registry updated 30 Sept 2026
Registry record: ClinicalTrials.govPhase 21 site
Not yet recruiting
NCT07838454
Exosome and Mesenchymal Stem Cell Treatment for Salivary Gland Dysfunction in Primary Sjögren Syndrome
Banu Erkal
Registry updated 24 Sept 2026
Registry record: ClinicalTrials.govEarly Phase 11 site
RecruitingChina
NCT07301164
Clinical Study of BCT301 Cell Injection Therapy for Refractory Autoimmune Diseases
Peking University Third Hospital
Registry updated 23 Sept 2026
Registry record: ClinicalTrials.govPhase 1/20 sites
Not yet recruiting
NCT06821659
Safety and Efficacy of Universal CAR-T Cells (UWD-CD19) Combined With Immunosuppressants in the Treatment of Refractory Autoimmune Diseases
Peking University Third Hospital
Registry updated 23 Sept 2026
Registry record: ClinicalTrials.govPhase 21 site
Not yet recruitingChina
NCT07836660
A Study of IBI355 in Participants With Moderate-to-Severe Sjögren's Disease
Innovent Biologics (Suzhou) Co. Ltd.
Registry updated 23 Sept 2026
Registry record: ClinicalTrials.govPhase 1/21 site
RecruitingChina
NCT06828042
Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases
Peking University Third Hospital
Registry updated 22 Sept 2026
Registry record: ClinicalTrials.govPhase 20 sites
Not yet recruiting
NCT07823790
ONO-4915 in Patients With Primary Sjogren's Disease
Ono Pharmaceutical Co., Ltd.
Registry updated 16 Sept 2026
Registry record: ClinicalTrials.govPhase 30 sites
Not yet recruiting
NCT07791199
Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study Completers
Bristol-Myers Squibb
Registry updated 3 Sept 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingUnited States
NCT06392711
Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Medical Xerostomia
University of Wisconsin, Madison
Registry updated 19 Aug 2026
Registry record: ClinicalTrials.govPhase 241 sites
Not yet recruitingAustria, Belgium, Bulgaria, Germany, Estonia, Spain
NCT07760818
A Study to Assess Efficacy and Safety of Efgartigimod in Adults With Sjogren's Disease-associated Sensorimotor Polyneuropathy or Sensory Polyneuropathy (SERENITY)
argenx
Registry updated 12 Aug 2026
Registry record: ClinicalTrials.govPhase 114 sites
RecruitingGermany, France, Italy, United States
NCT07041099
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease
Cullinan Therapeutics Inc.
Registry updated 11 Aug 2026
Registry record: ClinicalTrials.govPhase 111 sites
RecruitingFrance, Netherlands, United States
NCT06977724
A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE), Sjogren's Disease (SjD) and Rheumatoid Arthritis (RA)
AbbVie
Registry updated 10 Aug 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingAustralia
NCT07284797
A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune Diseases
Xencor, Inc.
Registry updated 3 Aug 2026
Registry record: ClinicalTrials.govPhase 254 sites
RecruitingBulgaria, Brazil, Germany, Spain, France, Italy
NCT06991114
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
Artiva Biotherapeutics, Inc.
Registry updated 31 Jul 2026 · The registries disagree on the status
Registry record: ClinicalTrials.govNo phase1 site
Not yet recruitingUnited States
NCT07732582
Sjogren's Mini-Pill Oral and Gut Microbiome Study
Tufts University
Registry updated 29 Jul 2026
Registry record: ClinicalTrials.govEarly Phase 11 site
Not yet recruitingChina
NCT07596680
CD19/BCMA-Targeted Universal CAR-T Cell Injection for the Treatment of Autoimmune Diseases
Nanjing Bioheng Biotech Co., Ltd.
Registry updated 16 Jul 2026
Registry record: ClinicalTrials.gov
The same sites as a list
- China29 open trials
- United States23 open trials
- France20 open trials
- Germany10 open trials
- Italy10 open trials
- Poland9 open trials
- Spain8 open trials
- Australia6 open trials
- Netherlands6 open trials
- Taiwan6 open trials
- Hungary5 open trials
- Belgium5 open trials
- Portugal5 open trials
- Canada4 open trials
- Bulgaria4 open trials
- Brazil4 open trials
- Slovakia3 open trials
- Denmark3 open trials
- Austria3 open trials
- Romania3 open trials
- Türkiye3 open trials
- Israel2 open trials
- South Korea2 open trials
- Serbia2 open trials
- Mexico2 open trials
- Argentina2 open trials
- Japan2 open trials
- Colombia1 open trial
- Georgia1 open trial
- India1 open trial
- Czechia1 open trial
- Lithuania1 open trial
- Estonia1 open trial
- Panama1 open trial
- Croatia1 open trial
- Peru1 open trial
- Chile1 open trial
- Greece1 open trial
- United Kingdom1 open trial
- New Zealand1 open trial
- Armenia1 open trial
Who treats this
Institutions with trials or publications in this disease (OpenAlex, registries). Institutions only, no people.
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
Mexico City, Mexico
1 trial · 4 publications · ROR
What changed in the last 7 days
Registry facts, one per line, newest first.
Opened for recruitment
NCT07737743 · Phase 2 · Austria, Australia, Belgium, Bulgaria, Canada, China
Source: ClinicalTrials.govStatus changed: Recruiting → Not yet recruiting
NCT07760818 · Phase 2 · Austria, Belgium, Bulgaria, Germany, Estonia, Spain
Source: ClinicalTrials.govClosed for recruitment
NCT06293365 · Phase 2 · Argentina, Canada, Czechia, Germany, Spain, Hungary
Source: ClinicalTrials.govClosed for recruitment
NCT05946941 · Phase 3 · Argentina, Austria, Australia, Belgium, Bulgaria, Brazil
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
NCT05349214 · Phase 3 · Argentina, Australia, Bulgaria, Brazil, Canada, Chile
Source: ClinicalTrials.govOpened for recruitment
NCT05946941 · Phase 3 · Argentina, Austria, Australia, Belgium, Bulgaria, Brazil
Source: ClinicalTrials.govOpened for recruitment
NCT07760818 · Phase 2 · Austria, Belgium, Bulgaria, Germany, Estonia, Spain
Source: ClinicalTrials.govStatus changed: Recruiting → Not yet recruiting
NCT07737743 · Phase 2 · Austria, Australia, Belgium, Bulgaria, Canada, China
Source: ClinicalTrials.govOpened for recruitment
NCT06293365 · Phase 2 · Argentina, Canada, Czechia, Germany, Spain, Hungary
Source: ClinicalTrials.gov
Results card
Trials that finished or stopped in the last 3 years, with the reason the registry gives and linked publications.
Phase 1/2Ended 20 Oct 2026
Completed29 participants
NCT07910526
Umbilical Cord Mesenchymal Stem Cell Secretome in Patients With Sjogren's Syndrome
Phase 3Ended 8 Oct 2026
Completed248 participants
NCT06684847
A Study of the Efficacy and Safety of Efgartigimod in Patients with Primary Sjögren's Syndrome (pSjD) (UNITY)
Phase 3Ended 25 Aug 2026
Completed182 participants
2023-503923-24-00
A study to find how well Dazodalibep works and how safe it is in participants with Sjögren’s Syndrome
Phase 3Ended 17 Aug 2026
No phaseEnded 30 Jun 2026
Completed101 participants
NCT07824440
a Salivary Cell-free RNA Liquid Biopsy Model for Non-invasive Diagnosis in Sjögren's Disease
Phase 3Ended 2 Jun 2026
Completed275 participants
NCT05350072
Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome
- Ianalumab for the Treatment of Patients with Sjögren's Disease. · The New England journal of medicine, 2026
Phase 2Ended 20 May 2026
Completed103 participants
NCT07264517
Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).
Phase 2Ended 12 Mar 2026
Completed151 participants
NCT06312020
A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjögren’s Syndrome
Phase 1Ended 5 Mar 2026
Stopped early116 participants
NCT06544642
A Study to Evaluate the Effects of ASP5502 in Healthy Adults and Adults With Primary Sjögren's Syndrome
Reason given: Company's strategic decision
No phaseEnded 28 Feb 2026
Completed57 participants
NCT07301892
Generative AI Impact on Rheumatoid Arthritis Complications Diagnosis
No phaseEnded 30 Jan 2026
Phase 2Ended 5 Jan 2026
Completed21 participants
NCT05124925
Biopsy Based Study to Understand Mechanism of Action of Ianalumab in Salivary Glands and Explore Relationships With Clinical Assessments.
No phaseEnded Dec 2025
Withdrawn before start0 participants
NCT02450396
Pregnancy and Medically Assisted Conception in Rare Diseases
Reason given: Abandonment of the study project
No phaseEnded 30 Dec 2025
Completed46 participants
NCT07469865
Efficacy and Safety of 20% and 100% Autologous Serum Eye Drops in Patients With Severe Dry Eye Disease (AST)
No phaseEnded 30 Nov 2025
Completed60 participants
NCT06398210
Investigation of the Effectiveness of Cognitive Exercise Therapy Approach in Patients With Primary Sjögren's Syndrome
Phase 2Ended 19 Sept 2025
No phaseEnded 15 Sept 2025
Phase 2Ended 21 Aug 2025
No phaseEnded 28 Jul 2025
Completed10 participants
NCT07248436
"Validity and Reliability of Pelvic Floor Distress Inventory-20 in Primary Sjögren's Syndrome"
Phase 1Ended 25 Jul 2025
Completed30 participants
NCT06484855
Safety and Tolerability of IBI355 in Patients With Primary Sjogren's Syndrome
Show more
No phaseEnded 19 Jul 2025
Completed26 participants
NCT06626477
Intra-Nasal Mechanical Stimulation (INMEST) as a Potential Treatment Method for Sjogren's Syndrome (SS)
Phase 3Ended 1 Jun 2025
Completed25 participants
NCT06931041
Comparing Efficacy of Autologous Serum Eye Drops With and Without Insulin in Autoimmune Dry Eye.
Phase 3Ended 6 May 2025
Completed381 participants
NCT05673993
A Study to Evaluate the Efficacy and Safety of Telitacicept in Subjects With Active Primary Sjogren's Syndrome
Phase 2Ended 17 Apr 2025
Completed116 participants
NCT06381986
Efficacy and Safety of SHJ002 Ophthalmic Solution in the Treatment of Corneal Erosion in Sjogren's Patients
Phase 3Ended 10 Apr 2025
Phase 2Ended 25 Feb 2025
Phase 2Ended 3 Feb 2025
Completed27 participants
2023-503915-14-00
Open-Label Extension (OLE) Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren’s Syndrome (pSS)
Phase 2/3Ended Jan 2025
Withdrawn before start0 participants
NCT04563195
BAFF/IL-17 Bispecific Antibody Treatment in Subjects With Primary Sjogren's Syndrome
Reason given: Drug unavailable
No phaseEnded 21 Jan 2025
No phaseEnded 10 Jan 2025
Stopped early103 participants
NCT06411132
Study to Evaluate Corneal Neurosensory Abnormalities in Patients With Sjögren's Dry Eye
Reason given: The analyses presented are based on a database lock date of 05 March 2025.The study was prematurely interrupted by Dompé following a review of the database, which determined that an acceptable no. of patients was reached to meet the trial objectives.
No phaseEnded 1 Jan 2025
Completed100 participants
NCT06410742
Comprehensive Evaluation of Clinical and Biopsychosocial Characteristics in Primary Sjögren's Disease
No phaseEnded 19 Dec 2024
Stopped early13 participants
NCT06364657
Differences in Corneal Structure and Function in Patients With Sjogrens vs. Non-Sjogrens Dry Eye
Reason given: The study was prematurely closed to enrollment due to the principal investigator's departure from the institution (Johns Hopkins University).
Phase 2Ended 22 Nov 2024
Phase 1/2Ended 11 Nov 2024
Stopped early8 participants
NCT06520202
RHPRG4 FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASE
Reason given: Efficacy signal substantial enough to move to a larger sturdy
No phaseEnded 31 Oct 2024
Completed236 participants
NCT02699190
LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies
No phaseEnded 30 Oct 2024
Completed1000 participants
NCT06437652
An AI Algorithm for Lymphocyte Focus Score of Minor Salivary Gland Biopsy Samples for Diagnosing Sjogren's Syndrome
Phase 2Ended 19 Aug 2024
Completed206 participants
NCT04541589
Study of Safety and Tolerability of CFZ533 in Patients With Sjögren's Syndrome
No phaseEnded 28 Jun 2024
Completed318 participants
NCT05961267
Study of Gynecological Follow-up of Patients With Autoimmune Disease or Inflammatory Rheumatism
- Cervical cancer screening practices among patients with autoimmune and inflammatory rheumatic diseases: a descriptive cross-sectional observational study. · BMC women's health, 2026
- Prevalence of effective contraceptive use among patients with rheumatic diseases: a descriptive study. · BMC rheumatology, 2026
No phaseEnded Apr 2024
No phaseEnded 1 Apr 2024
Completed54 participants
NCT06363955
Assessing the Efficacy of a Carbamide Peroxide Mouthwash for Oral Wound Healing, Oral Hygiene and Xerostomia Relief
Phase 1/2Ended 31 Mar 2024
Phase 4Ended 21 Mar 2024
No phaseEnded 22 Feb 2024
Completed74 participants
NCT04546542
Hydroxychloroquine Blood Levels in Primary Sjögren Syndrome Patients
Phase 2Ended 9 Feb 2024
Completed84 participants
NCT04572841
Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Primary Sjögren's Syndrome (pSjS)
No phaseEnded 31 Dec 2023
Completed100 participants
NCT05656196
VGH-DESJS-1 in Ocular and Oral Dryness Symptoms of Dry Eye Syndrome and Sjögren's Syndrome
Phase 3Ended 11 Dec 2023
Phase 2Ended 30 Nov 2023
Completed163 participants
NCT04968912
A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS)
- Effect of nipocalimab on IgG responses to vaccinations and viral infections in patients with IgG autoantibody-mediated diseases: Post hoc analyses of three randomized, placebo-controlled trials. · Human vaccines & immunotherapeutics, 2026
- Efficacy and safety of nipocalimab in patients with moderate-to-severe Sjögren's disease (DAHLIAS): a randomised, phase 2, placebo-controlled, double-blind trial. · Lancet (London, England), 2025
Not medical advice. fetched 10 Nov 2026